Press-release for stocks for nvs

Prices are updated after-hours

| 7.77% | O: -1.03% H: 0.24% C: -0.15%
BGNE S | $131.94 0.06% 0.06% 130K

| -48.93% | O: 8.83% H: 0.11% C: -4.16%
novartis license immunotherapy therapy collaboration

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K

| 9.07% | O: -0.06% H: 0.0% C: 0.0%
NVS | News | $92.57 -0.55% 0.0% 910K

| 9.06% | O: 0.56% H: 0.3% C: 0.19%
fda application license biosimilar

| 7.77% | O: -1.03% H: 0.24% C: -0.15%
BGNE S | $131.94 0.06% 0.06% 130K

| -48.93% | O: 8.83% H: 0.11% C: -4.16%
novartis china collaboration

Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
Published: 2021-12-20 (Crawled : 07:00) - globenewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K

| 7.77% | O: -1.03% H: 0.24% C: -0.15%
qge031 novartis urticaria

64%

36%

AGBA | $1.02 155.0% 57.94% 120M

ZCMD | $2.86 108.76% 52.1% 2.3M

INVO | $1.555 104.6% 51.13% 5M

ISPC | $0.437 105.16% 49.53% 37M

WLGS | $0.92 84.0% 45.65% 1.6M

OST | $0.499 21.38% 45.26% 1.9M

XPON | $3.1 60.62% 37.74% 17M

TIRX | $0.7 44.39% 30.74% 58M

BNTC | $6.92 44.17% 30.64% 3.5M

GGE | $0.035 19.86% 29.3% 64M

Save your searches and get alerts when important news are released.